Vitamin D receptor agonists' anti-inflammatory properties

Annals of the New York Academy of Sciences

Volumn 1317, Issue 1, 2014, Pages 47-56

  Vojinovic, Jelena ^a  

^a UNIVERSITY OF NI   (Serbia)

Author keywords

Inflammation; VDR agonist; Vitamin D; Vitamin D receptor (VDR)

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 20 EPICALCITRIOL; 22 OXACALCITOL; ALFACALCIDOL; ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CHEMOKINE; CYTOCHROME P450; CYTOKINE; ELOCALCITOL; GLUCOCORTICOID; HORMONE ANALOG; HORMONE RECEPTOR STIMULATING AGENT; LEXACALCITOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; RALOXIFENE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SEOCALCITOL; TX 522; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTHRITIS; ARTICLE; BONE TURNOVER; BREAST CANCER; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; COLON CANCER; DIETARY INTAKE; DRUG SAFETY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEREDITY; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MYELOID LEUKEMIA; MYOPATHY; NONHUMAN; OSTEOPOROSIS; OVERACTIVE BLADDER; PANCREAS CANCER; PROSTATE CANCER; PROSTATE HYPERTROPHY; PSORIASIS; RHEUMATOID ARTHRITIS; THYROID CARCINOMA; VITAMIN INTAKE;

INFLAMMATION; VDR AGONIST; VITAMIN D; VITAMIN D RECEPTOR (VDR);

ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCITRIOL; EPIGENESIS, GENETIC; HUMANS; RECEPTORS, CALCITRIOL; RHEUMATIC DISEASES;

EID: 84901505622     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12429     Document Type: Article

References (91)

1. Nobelprize.org. 2013. The Nobel Prize in Physiology or Medicine 1903. Nobel Media AB 2013. Accessed April 5, 2014. http://nobelprize.org/nobel_prizes/medicine/laureates/1903/finsen-bio.html.
2. Haussler, M.R. et al. 2010. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. J. Steroid. Biochem. Mol. Biol. 121: 88-97.
3. Arnson, Y. et al. 2007. Vitamin D and autoimmunity new etiological and therapeutical considerations. Ann. Rheum. Dis. 66: 1137-1142.
4. Pludowski, P. et al. 2013. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 12: 976-989.
5. Wacker, M. & M.F. Holick 2013. Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 5: 111-148.
6. De Luca, H. 2004. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 80: 1689S-1696S.
7. Andjelkovic, Z. et al. 1999. Disease modifynig and immunoregulatory effects of high oral dose 1α(OH)D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 17: 59-62.
8. Antico, A. et al. 2012. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 12: 127-136.
9. Adorini, L. 2002. 1, 25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr. Opin. Investig. Drugs. 3: 1458-1463.
10. De Luca, H.F. 1974. Vitamin D: the vitamin and the hormone. Fed. Proc. 33: 2211-2219.
11. Cheng, J.B. et al. 2004. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. U. S. A. 101: 7711-7715.
12. Jurutka, P.W. et al. 2007. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J. Bone Miner. Res. 22: V2-V10.
13. Adams, J.S. & M. Hewison 2010. Update in vitamin D. J. Clin. Endocrinol. Metab. 95: 471-478.
14. Mora, R. et al. 2008. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol. 8: 685-698.
15. Cutolo, M. et al. 2011. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun. Rev. 11: 84-87.
16. Bjelakovic, G. et al. 2011. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. 7: CD007470.
17. Margolis, R.N. & S. Christakos 2010. The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation. Ann. N. Y. Acad. Sci. 1192: 208-214.
18. Lonard, D.M. et al. 2007. Nuclear receptor coregulators and human disease. Endocr. Rev. 28: 575-587.
19. Eduardo-Canosa, S. et al. 2010. Design and synthesis of active vitamin D analogs. J. Steroid. Biochem. Mol. Biol. 121: 7-12.
20. Norman, A.W. 2006. Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147: 5542-5548.
21. Nagpal, S. et al. 2005. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26: 662-687.
22. Carlberg, C. & F. Molnár 2012. Current status of vitamin D signaling and its therapeutic applications. Curr. Topics Med. Chem. 12: 1-20.
23. Ranganathan, P. 2009. Genetics of bone loss in rheumatoid arthritis-role of vitamin D receptor polymorphisms. Rheumatology 48: 342-346.
24. Maalej, A. et al. 2005. Association study of VDR gene with rheumatoid arthritis in the French population. Genes Immun. 6: 707-711.
25. Huhtakangas, J.A. et al. 2004. The vitamin D receptor is present in caveolae enriched plasma membranes and binds 1α, 25(OH)2-vitamin D3 in vivo and in vitro. Mol. Endocrinol. 18: 2660-2671.
26. Hossein-Nezhad, A. & M.F. Holick 2012. Optimize dietary intake of vitamin D: an epigenetic perspective. Curr. Opin. Clin. Nutr. Metab. Care 15: 567-579.
27. Razin, A. 1998. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J. 17: 4905-4908.
28. Narlikar, G.J. et al. 2002. Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487.
29. Vojinovic, J. & N. Damjanov 2011. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol. Med. 7: 397-403.
30. Takeyama, K.I. & S. Kato The vitamin D3 1alpha-hydroxylase gene and its regulation by active vitamin D3. Biosci. Biotechnol. Biochem. 75: 208-213.
31. Carlberg, C. 2003. Molecular basis of the selective activity of vitamin D analogues. J. Cell. Biochem. 88: 274-281.
32. Chawla, A. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science 294: 1866-1870.
33. Nagy, L. & J.W. Schwabe 2004. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29: 317-324.
34. Bouillon, R. et al. 1995. Structure-function relationships in the vitamin D endocrine system. Endocrine. Rev. 16: 200-257.
35. Schacht, E. & J.D. Ringe 2012. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int. 32: 207-215.
36. Pernalete, N. et al. 1991. The activity of 22-oxacalcitol in osteoblast-like (ROS17/2.8) cells. Endocrinology 129: 778-784.
37. Dore, B.T. et al. 1993. Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. Leuk. Res. 17: 749-757.
38. Kumgai, T. et al. 2003. Vitamin D2 analog 19-nor-1, 25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma and colon cancer. J. Natl. Cancer. Inst. 95: 896-905.
39. Koeffler, H.P. et al. 2005. Vitamin D(2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk. Res. 29: 1259-1262.
40. Mathieu, C. et al. 1995. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1, 25-dihydroxyvitamin D3, KH1060. Endocrinology 136: 866-872.
41. Stio, M. et al. 2001. Suppressive effect of 1, 25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem. Pharmacol. 61: 365-371.
42. Colston, K.W. et al. 1992. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 44: 2273-2280.
43. Mathiasen, I.S. et al. 1999. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer. Res. 59: 4848-4856.
44. Evans, T.R. et al. 2002. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer. 86: 680-685.
45. Digesu, G.A et al. 2012. Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity. Urology 80: 48-54.
46. Di Luigi, L. et al. 2013. The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One 8: e77745.
47. Larsson, P. et al. 1998. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin. Exp. Immunol. 114: 277-283.
48. Segaert, S. & M. Ropke 2013. The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis. J. Drugs Dermatol. 12: 129-137.
49. Laverny, G. et al. 2009. Synthesis and anti-inflammatory properties of 1alpha, 25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha, 25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3. J. Med. Chem. 52: 2204-2213.
50. Laverny, G. et al. 2010. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol. Lett. 131: 49-58.
51. Penna, G. et al. 2009. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J. Immunol. 182: 4056-4064.
52. Kashiwagi, H. et al. 2011. Novel nonsecosteroidal vitamin D3 carboxylic acid analogs for osteoporosis, and SAR analysis. Bioorg. Med. Chem. 19: 4721-4729.
53. Peräkylä, M. et al. 2005. Gene regulatory potential of nonsteroidal vitamin D receptor ligands. Mol. Endocrinol. 19: 2060-2073.
54. Gajewski, R. et al. 2006. Phenyfuran compounds as vitamin D receptor modulators. World Patent 051936.
55. So, J.Y. et al. 2013. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One 8: 54020.
56. Norman, A. et al. 1990. Structure-function studies on analogues of 1 alpha, 25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res. 50: 6857-6864.
57. Maggi, M. et al. 2006. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J. Endocrinol. Invest. 29: 665-674.
58. Tocchini-Valentini, G. et al. 2001. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. U. S. A. 98: 5491-5496.
59. Tocchini-Valentini, G. et al. 2004. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J. Med. Chem. 47: 1956-1961.
60. Uskokovic, M. et al. 2006. C-20 cyclopropyl vitamin D3 analogs. Curr. Top. Med. Chem. 6: 1289-1296.
61. Asano, L. et al. 2013. Structural basis for vitamin D receptor agonism by novel non-secosteroidal ligands. FEBS Lett. 587: 957-963.
62. Herdick, M. et al. 2000. Response element- and coactivator-mediated conformational change of the vitamin D3 receptor permits sensitive interaction with agonists. Mol. Pharmacol. 57: 1206-1217.
63. Cantorna, M.T. et al. 2000. 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 130: 2648-2652.
64. Lemire, J.M. & D.C. Archer 1991. 1, 25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87: 1103-1107.
65. Cantorna, M.T. et al. 1996. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93: 7861-7864.
66. Nataf, S. et al. 1996. 1, 25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol. 55: 904-914.
67. Casteels, K. et al. 1998. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 65: 1225-1232.
68. Hein, G. & P. Oelzner 2000. Vitamin D metabolites in rheumatoid arthritis: findings-hypotheses-consequences. Z. Rheumatol. 59: 28-32.
69. Yamauchi, Y. et al. 1989. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi 29: 11-24.
70. Vojinovic, J. et al. 2012. Alphacalcidol (D-hormone analog) modulate inflammatory cytokine production without conversion to calcitriol. Ann. Rheum. Dis. 1(Suppl 3.): 672.
71. Veldman, C.M. et al. 2000. Expression of 1, 25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 374: 334-338.
72. van Etten, E. & C. Mathieu 2005. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J. Steroid. Biochem. Mol. Biol. 97: 93-101.
73. Adorini, L. et al. 2004. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol. 16: 1271-1234.
74. Adams, J.S. & M. Hewison 2008. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 4: 80-90.
75. Liu, P.T. et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
76. Adorini, L et al. 2008. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4: 404-412.
77. Colin, E.M. et al. 2010. 1, 25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 62: 132-142.
78. Sternberg, Z. 2012. Autonomic disfunction: a unifying multiple sclerosis theory linking chronic cerebrospinal venous insufficiency, vitamin D3, and Epstein-Barr virus. Autoimmun. Rev. 12: 250-259.
79. Steinman, L. 2007. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13: 139-145.
80. Tang, J. et al. 2009. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol. 182: 4624-4632.
81. Daniel, C. et al. 2008. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 324: 23-33.
82. Di Rosa, M. et al. 2013. Vitamin D3 insufficiency and colorectal cancer. Crit. Rev. Oncol. Hematol. 88: 594-612.
83. Allavena, P. et al. 2008. Pathways connecting inflammation and cancer. Curr. Opin. Gen. Develop. 18: 3-10.
84. 3 inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr. Med. Chem. 20: 4131-4141.
85. Mantovani, A. et al. 2008. Cancer-related inflammation. Nature 454: 436-444.
86. Krishnan, A.V. & D. Feldman 2010. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer 17: R19-R38.
87. Villagio, B. et al. 2012. 1, 25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin. Exp. Rheumatol. 30: 934-938.
88. Cutolo, M. 2012. The challenges of using vitamin D in cancer prevention and prognosis. Isr. Med Assoc. J. 14: 637-639.
89. Krishnan, A.V. et al. 2012. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 77: 1107-1112.
90. Beer, T.M. et al. 2007. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 25: 669-674.
91. Crew, K.D. 2013. Vitamin D: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol. doi:10.1155/2013/483687.